Cure My Disease

Don't miss your cure!

 Log in / Sign up

New immune cell combo tackles tough lymphoma

NCT ID NCT07283679

Recruiting now Disease control Sponsor: M.D. Anderson Cancer Center Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether a special type of immune cell (ONC-PluReceptor NK cells) given with two antibody drugs (epcoritamab and tafasitamab) can control B-cell Non-Hodgkin lymphoma that has come back or not responded to prior treatments. About 30 adults aged 18-80 who have already tried at least two other therapies or a stem cell transplant will take part. The main goals are to check safety and see if the combination helps shrink or stop the cancer.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RECURRENT B-CELL NON-HODGKIN LYMPHOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

B-cell neoplasm B-cell non-Hodgkin lymphoma follicular lymphoma relapsed/refractory diffuse large B-cell lymphoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RECURRENT B-CELL NON-HODGKIN LYMPHOMA REFRACTORY B-CELL NON-HODGKIN LYMPHOMA

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • The University of Texas M. D. Anderson Cancer Center

    RECRUITING

    Houston, Texas, 77030, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.